Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took Vivotif on day one, three, four and five; Case reference number US-BN-2025-001584 is a spontaneous case initially received from a nurse via Communications (reference number: USBAV25-2357) on 23-Sep-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, also reported as day one, the patient took the first dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally, for an unknown indication. On an unspecified date, reported as day three, the patient took the second dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally. On an unspecified date, reported as day four, the patient took the third dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). On an unspecified date, reported as day five, the patient took the fourth dose of Vivotif vaccine (batch number: unknown) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender took the third and the fourth dose of Vivotif vaccine for an unknown indication, on the days 4 and 5 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender took the third and the fourth dose of Vivotif vaccine for an unknown indication, on the days 4 and 5 after the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE